AI and advanced scans aim to predict prostate Cancer's next move

NCT ID NCT03594760

Recruiting now Diagnosis Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether combining a special PET scan (PSMA-PET) with artificial intelligence can help predict how prostate cancer will behave. Researchers will scan 1,000 men with prostate cancer and use deep learning to find patterns in the images that link to survival and disease progression. The goal is to develop better tools to guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-DCFPyL (a radioactive tracer for PET imaging)
What this could lead to: If successful, this could lead to a new way to predict how prostate cancer will progress and which treatments will work best for each patient.
What could go wrong: This is an observational imaging study, not a treatment trial. The AI models may not prove accurate enough for routine use, and results may not apply to all prostate cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Centre Hospitalier de l'université de Montréal
RECRUITING

Montreal, Quebec, H2X 0C1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.